Fast-growing Duoning Biotech seeks winning formula for pricey IPO
The provider of bioprocessing services for the drugs sector has been expanding rapidly via aggressive M&A, backed by big-name investors Key Takeaways: WuXi Biologics is Duoning Biotechnology’s biggest client and…
RELATED ARTICLES
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK -
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
- CHINA BULLETIN: Manufacturing Déjà Vu
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
